CytoMed Therapeutics Limited GDTC
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $252,265, +395.9% YoY · Filed Mar 31, 2026
CytoMed Therapeutics Limited (GDTC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $252,265 and a net loss of $3.1 million. Free cash flow was -$3.4 million. As of Dec 31, 2025 it held $1.6 million in cash and investments and $375,272 in total debt.
Revenue
$252,265
+395.9% vs prior year
Net income
$-3.11M
-68.4% vs prior year
Operating cash flow
$-2.88M
-45.0% vs prior year
Free cash flow
$-3.37M
-12.1% vs prior year
EPS
$-0.27
-68.8% vs prior year
Dividend per share
None
Shares outstanding
11.83M
+2.5% vs prior year
Net cash
$1.25M
FY 2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GDTC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Singapore
- Headquarters
- 1 Commonwealth Lane, Singapore
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1873093
- Former names
- CytoMed Therapeutics Pte. Ltd. (until Nov 30, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $252,265 | $50,872 | — | — |
| Net income | -$3.1M | -$1.8M | -$3.1M | -$2.3M |
| Diluted EPS | -$0.27 | -$0.16 | -$0.29 | -$0.30 |
| Operating cash flow | -$2.9M | -$2.0M | -$2.6M | -$1.0M |
| Free cash flow | -$3.4M | -$3.0M | -$2.6M | -$1.4M |
| Total assets | $6.2M | $7.4M | $9.4M | $3.9M |
| Total liabilities | $879,762 | $749,495 | $852,508 | $3.5M |
| Stockholders' equity | $5.3M | $6.6M | $8.5M | $437,405 |
| Cash and investments | $1.6M | $3.7M | $4.6M | $1.2M |
| Total debt | $375,272 | $339,079 | $339,590 | $610,284 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 9, 2026 |
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jun 23, 2026 | Jun 23, 2026 |
| 6-K | Current report (foreign issuer) | Jun 3, 2026 | Jun 3, 2026 |
| 6-K | Current report (foreign issuer) | May 15, 2026 | May 15, 2026 |
| 6-K | Current report (foreign issuer) | May 11, 2026 | May 11, 2026 |
All 132 CytoMed Therapeutics Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.